Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Commentary|Podcasts|July 23, 2024
Frameworks for Advancing Health Equity: Health Equity by Design
Author(s)Giuliana Grossi
Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
Advertisement
This episode is another installment of the
Melissa Clarke, MD, CMQ, the chief health equity officer at
Frameworks for Advancing Health Equity episodes:
Listen above or on one of these podcast services:
Advertisement
Related to this article
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Endometriosis was found to nearly double absenteeism and work-ability impairment, according to one study.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
Across the US, Obesity Care Still Lacks an Owner
4
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
5